An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K. regulators cleared Sarepta to restart an Elevidys study and Altos Labs ...

Leaders must re-examine the healthcare supply network and shift the focus from cost savings to building resilience—all while ...

Three years ago, as the pandemic caused chaos for companies big and small, Colgate-Palmolive’s chief supply chain officer ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

Still, with supply chain constraints largely in the rearview ... Drug Manufacturers—General A household name among drug manufacturers, Pfizer stock is currently trading at a 43% discount to ...

AI-generated computer code is rife with references to non-existent third-party libraries, creating a golden opportunity for supply-chain attacks that poison legitimate programs with malicious ...

Overall, the environment is extremely uncertain. Pfizer operates globally, and its supply chain significantly depends on geopolitical stability. Since the current geopolitical landscape looks ...

LONDON, April 24, 2025--(BUSINESS WIRE)--Manhattan Associates Inc. (NASDAQ: MANH) today announced that it has received the 2025 Google Cloud Business Applications Partner of the Year Award for ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. The Big Pharma disclosed the blow alongside a $200 million charge linked ...